DAX22.391 -0,7%ESt505.304 -0,3%Top 10 Crypto12,09 -0,5%Dow42.225 +0,6%Nas17.601 +0,9%Bitcoin77.421 -1,9%Euro1,0808 -0,2%Öl73,37 -1,5%Gold3.138 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 RENK RENK73 thyssenkrupp 750000 Novo Nordisk A3EU6F Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 Bayer BAY001 HENSOLDT HAG000 Volkswagen (VW) vz. 766403 Commerzbank CBK100 Amazon 906866 Deutsche Telekom 555750 Siemens Energy ENER6Y
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Dow letztlich im Plus -- DAX schließt tiefer -- Tesla: Auslieferungen in Q1 gefallen -- Trump kündigt neues weitreichendes Zollpaket an - Rheinmetall, CoreWeave, Palantir im Fokus
Top News
Siemens-Aktie im Plus: Übernahme von Dotmatics Siemens-Aktie im Plus: Übernahme von Dotmatics
Trump kündigt neues weitreichendes Zollpaket an Trump kündigt neues weitreichendes Zollpaket an
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Coupon-Jäger aufgepasst - alles zu Aktienanleihen gibt’s von Birgit heute im gettex-podcast mit Lars und Christian Schlegel

AbbVie Aktie

NeuKaufenVerkaufen
AbbVie Aktien-Sparplan
188,64 EUR -3,68 EUR -1,91 %
STU
205,00 USD -0,09 USD -0,04 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.338,27 Mrd. EUR

KGV74,34Div. Rendite3,54%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
PR NewswireAllergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industry
PR NewswireSKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
PR NewswireAbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hemat...
PR NewswireAbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients
PR NewswireNew Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment
PR NewswireAbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting
PR NewswireABBV LAWSUIT ALERT: Levi & Korsinsky Notifies AbbVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
PR NewswireABBV Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of AbbVie, Inc. of Deadline in Securities Fraud Class Action Lawsuit
PR NewswireABBVIE INC. (NYSE: ABBV) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against AbbVi...
PR NewswireAbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
PR NewswireABBV ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 6, 2022 in the Class Action Filed on Behalf of AbbVie Inc. Shareholders
PR NewswireThe Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
PR NewswireThe Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
PR NewswireAbbVie, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds ABBV Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf
PR NewswireAbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference
PR NewswireAbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV
PR NewswireAbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
PR NewswireAbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week®
PR NewswireAbbVie and Cugene Announce Collaboration in Autoimmune Diseases
PR NewswireAbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses
PR NewswireAbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education
PR NewswireUpadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease
PR NewswireSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 6, 2022 - (NYSE: ABBV)
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV
PR NewswireRINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
PR NewswireAbbVie Reports First-Quarter 2022 Financial Results
PR NewswireAllergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
PR NewswireAbbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
PR NewswireHealth Canada Approves VRAYLAR® (cariprazine) for the Treatment of Bipolar l Disorder and Schizophrenia in Adults
PR NewswireTOP RANKED ROSEN LAW FIRM Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV
PR NewswireDragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases
PR NewswireAllergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
PR NewswireAbbVie to Host First-Quarter 2022 Earnings Conference Call
PR NewswireAbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
PR NewswireBOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval
PR NewswireAbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV
Wer­bung

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.